Share information
277.80 €
+0.47 %
04/11/2026 10:03
+0.47 %
Open
High
Low
Volume
277.40 €
278.80 €
275.70 €
9,324
Latest News
04-Nov-2026
UCB advances its digital antibody engineering program with new Cradle collaboration
22-Oct-2026
Strong Performance Drives Further Upgrade to UCB’s 2026 Financial Guidance
19-Oct-2026
Transparency notification Wellington
16-Oct-2026
UCB announces U.S. FDA approval for ZILBRYSQ[®] (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis